Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$10.5 - $14.2 $71,400 - $96,560
6,800 Added 11.24%
67,300 $8,000
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $144,586 - $198,454
13,400 Added 28.45%
60,500 $31,000
Q2 2022

Aug 12, 2022

SELL
$7.89 - $17.88 $164,112 - $371,904
-20,800 Reduced 30.63%
47,100 $9,000
Q1 2022

May 12, 2022

SELL
$11.56 - $19.76 $273,972 - $468,312
-23,700 Reduced 25.87%
67,900 $58,000
Q4 2021

Feb 14, 2022

BUY
$11.18 - $15.46 $488,566 - $675,602
43,700 Added 91.23%
91,600 $98,000
Q3 2021

Nov 10, 2021

BUY
$14.21 - $17.65 $52,577 - $65,304
3,700 Added 8.37%
47,900 $55,000
Q2 2021

Aug 11, 2021

SELL
$9.5 - $17.24 $356,250 - $646,499
-37,500 Reduced 45.9%
44,200 $167,000
Q1 2021

May 14, 2021

SELL
$7.37 - $13.61 $1.18 Million - $2.18 Million
-160,400 Reduced 66.25%
81,700 $139,000
Q4 2020

Feb 16, 2021

BUY
$3.37 - $8.61 $736,682 - $1.88 Million
218,600 Added 930.21%
242,100 $403,000
Q3 2020

Nov 13, 2020

SELL
$3.43 - $5.53 $124,166 - $200,186
-36,200 Reduced 60.64%
23,500 $13,000
Q2 2020

Aug 10, 2020

BUY
$1.9 - $5.61 $25,650 - $75,735
13,500 Added 29.22%
59,700 $45,000
Q1 2020

May 08, 2020

BUY
$1.6 - $4.11 $30,400 - $78,090
19,000 Added 69.85%
46,200 $9,000
Q4 2019

Feb 11, 2020

BUY
$1.59 - $3.45 $43,248 - $93,840
27,200 New
27,200 $12,000
Q3 2019

Nov 12, 2019

SELL
$2.5 - $3.73 $50,250 - $74,973
-20,100 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$2.91 - $9.15 $58,491 - $183,915
20,100 New
20,100 $0

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.